Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.33 |
| ▸ | RELA | Q04206 | 2/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662104 | 1.00 | JUN (0.33) | JUNNFKB1NFKB2RELARPS6KA5 | |
| SCHEMBL29174727 | 0.80 | RPS6KA5 (0.43) | RPS6KA5 | |
| SCHEMBL30725466 | 0.80 | RPS6KA5 (0.43) | RPS6KA5 | |
| SCHEMBL21410120 | 0.76 | KDM5B (0.31) | — | |
| SCHEMBL29699016 | 0.71 | NFKB1 (0.35) | JUNNFKB1NFKB2RELARPS6KA5 | |
| SCHEMBL19100425 | 0.70 | CCNK (0.54) | — | |
| SCHEMBL153856 | 0.68 | RPS6KA5 (0.42) | JUNNFKB1NFKB2RELARPS6KA5 | |
| SCHEMBL29392215 | 0.68 | RPS6KA5 (0.42) | JUNNFKB1NFKB2RELARPS6KA5 | |
| SCHEMBL27503715 | 0.68 | NPC1 (0.41) | JUNNFKB1NFKB2RELA | |
| SCHEMBL19605660 | 0.67 | CCNT1 (0.41) | RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| EP-3782986-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019189555-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | CDK1, CDK12, CDK15 | JUN 2247/4885NFKB1 2081/4885NFKB2 1403/4885 |
| US-11584737-B2 | Heterocyclic compound | CDK12, CDK1, CDK15 | JUN 1814/4885NFKB1 1701/4885NFKB2 1062/4885 |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | CDK12, CDK1, CDK15 | JUN 1814/4885NFKB1 1701/4885NFKB2 1062/4885 |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | CDK1, CDK12, CDK15 | JUN 2247/4885NFKB1 2081/4885NFKB2 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.